Liquid pharmaceutical formulations of palonosetron
DC CAFCFirst Claim
Patent Images
1. A pharmaceutically stable intravenous solution for reducing emesis or reducing the likelihood of emesis comprising:
- a) from 0.03 mg/ml to 0.2 mg/ml palonosetron or a pharmaceutically acceptable salt thereof, buffered at a pH of from 4.0 to 6.0; and
b) a pharmaceutically acceptable sterile aqueous carrier including a tonicifying effective amount of mannitol and from 0.005 mg/ml to 1.0 mg/ml EDTA.
7 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
39 Citations
14 Claims
-
1. A pharmaceutically stable intravenous solution for reducing emesis or reducing the likelihood of emesis comprising:
-
a) from 0.03 mg/ml to 0.2 mg/ml palonosetron or a pharmaceutically acceptable salt thereof, buffered at a pH of from 4.0 to 6.0; and b) a pharmaceutically acceptable sterile aqueous carrier including a tonicifying effective amount of mannitol and from 0.005 mg/ml to 1.0 mg/ml EDTA. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A pharmaceutically stable isotonic intravenous solution for reducing emesis or reducing the likelihood of emesis comprising:
-
a) from 0.01 mg/ml to 5 mg/ml palonosetron or a pharmaceutically acceptable salt thereof, at a pH of from 4.0 to 6.0; and b) an aqueous pharmaceutically acceptable carrier including a chelating agent. - View Dependent Claims (9, 10, 11, 12, 13, 14)
-
Specification